Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
about
Vaccination for hepatitis C virus: closing in on an evasive targetAn update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesNext Steps Toward Eradication of Hepatitis C in the Era of Direct Acting AntiviralsSystematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implicationsNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewAntiviral treatment of hepatitis C virus infection and factors affecting efficacyEmerging therapies for hepatitis CEmerging therapeutic options for the management of hepatitis C infectionDirect acting antivirals for the treatment of chronic viral hepatitisA pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infectionHepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific regionDevelopment of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisionsThe Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease InhibitorsToward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing AntibodyStructural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization EscapeThe relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.Anti-hepatitis C virus drugs and kidneyS-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponseIL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyHCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsBoceprevir for untreated chronic HCV genotype 1 infectionSafety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.Hepatitis C treatment: where are we now?Advances in the treatment of hepatitis C virus infectionTelaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients.Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modellingInfluence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C.Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.Expression of selected genes in liver biopsy specimens in relation to early virological response in patients with chronic hepatitis C with HCV mono- and HIV/HCV co-infection.Risk perception and priority setting for intervention among hepatitis C virus and environmental risks: a cross-sectional survey in the Cairo community.Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy.Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.Hepatitis C virus NS3 mutations in haemophiliacsIdentification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.
P2860
Q22305922-5F4F667E-36B5-4B18-97E4-7192149402A2Q24632766-C4411D10-BCFD-4015-8FD5-889F1EE7494DQ26747561-55DFA569-F7E2-40BE-9B9B-AFACBF88B914Q26768128-6A86C604-DD74-4EDB-AF0A-C8AEDFDBD962Q26798477-5C06F9CF-5E65-44AF-9F67-832772A4B944Q26800050-8ABC53B3-82DB-4E09-984A-4857A604A0D4Q26851810-706C1CB8-4C09-4F4A-8782-E87940044C1FQ26853642-A91079DE-B84B-495B-8256-A3B9B21B45EBQ27012744-CA7A00DF-25E8-457B-A322-29A6566D29ACQ27022216-63CAAE05-7A1C-4A3F-8D09-1A272B4338EDQ27023355-5AD9CC41-75A9-4EB2-B2CE-D462A0DA56F6Q27026753-FD2A2B95-AB90-408A-A68F-D8CA8173C95CQ27468990-A2ED8C3A-5A66-4C8D-8D14-7C3D2E0554F6Q27671640-51E4DF9D-AC84-4281-9B94-0B8F501D6906Q27673453-63C84FB7-BEB9-41B9-AAFC-530E1FB6BBD5Q27678252-737F8FE3-CA1F-48FA-A886-9B47FAFC25F5Q27690869-29778566-648C-4FCE-9C3E-EA4D146208CAQ28070279-96EB3968-498A-4741-BF8C-BAFDCBFC52D1Q28476040-58768EEB-43B2-4506-8C12-A288C7C054F7Q28477057-A60E046B-F30E-4618-A96E-B59DF0208A99Q28481038-2B963CDC-9455-429C-8F6B-7F355C2BFE8CQ29620617-F5A80E6B-C9C0-4A62-AB90-7CCE598DEB55Q30361098-BAF29038-CF20-4E05-83E1-C686126C2088Q30378509-0E934D11-CDFA-4B6D-936E-8DF326D22481Q30415138-2DAAB35F-ACA9-4FE3-A215-EFF2F88945DAQ30430083-C12CC86F-BD02-48DA-A9B4-47651847B072Q30583856-6F3B7504-1A57-49AA-BAD9-1326C900E546Q30655795-E7A4B9DB-4D1C-4E33-94FB-623687090C50Q33424681-C4E3BD2D-B0FB-4731-A5BE-0372FB3ECB24Q33455220-A726228D-B432-455B-A833-B4755A7A03BEQ33701131-E2D05B96-6DEA-4D79-9A16-8E97A3E44F34Q33776139-8E29FED7-D73B-431F-8B9E-55CAF26DD90CQ33780237-2174809B-30C4-4CAA-BBB5-95F83A0079E9Q33800146-D3F4A173-C337-4259-988B-3B7475005005Q33853664-BBC88588-3A54-4FB0-9997-E85CACB9CDE6Q33878202-53A89682-5BB2-46C1-9010-24A81BAB4686Q33988984-73E6C5A0-5BEA-4E3A-A285-B93322E80B7FQ34111759-DAFF4FD9-907A-4C50-8FBC-E8D42DE97B96Q34112859-E649EFD5-D52A-40CB-8D26-5272B9476138Q34143327-ED2E6EF5-948E-4E3F-B88F-1E3B1CE09C69
P2860
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Efficacy of boceprevir, an NS3 ...... ed, multicentre phase 2 trial.
@en
Efficacy of boceprevir, an NS3 ...... ed, multicentre phase 2 trial.
@nl
type
label
Efficacy of boceprevir, an NS3 ...... ed, multicentre phase 2 trial.
@en
Efficacy of boceprevir, an NS3 ...... ed, multicentre phase 2 trial.
@nl
prefLabel
Efficacy of boceprevir, an NS3 ...... ed, multicentre phase 2 trial.
@en
Efficacy of boceprevir, an NS3 ...... ed, multicentre phase 2 trial.
@nl
P2093
P1433
P1476
Efficacy of boceprevir, an NS3 ...... ed, multicentre phase 2 trial.
@en
P2093
Clifford A Brass
David Pound
Eirum Chaudhri
Eric J Lawitz
Eugene R Schiff
Frank H Anderson
Ira M Jacobson
Janice K Albrecht
John M Vierling
Jonathan McCone
P304
P356
10.1016/S0140-6736(10)60934-8
P407
P577
2010-08-06T00:00:00Z